Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 49 Breast Neoplasms 49 Prostatic Neoplasms 47 Carcinoma, Non-Small-Cell Lung 47 Squamous Cell Carcinoma of Head and Neck 37 Lung Neoplasms 29 Head and Neck Neoplasms 26 Glioma 22 Rectal Neoplasms 21 Sarcoma 20 Neoplasms 20 Brain Neoplasms 20 Oropharyngeal Neoplasms 16 Esophageal Neoplasms 15 Uterine Cervical Neoplasms 14 Neoplasm Metastasis 14 Astrocytoma 13 Triple Negative Breast Neoplasms 12 Esophageal Squamous Cell Carcinoma 12 Carcinoma, Hepatocellular 12 Pancreatic Neoplasms 11 Melanoma 11 Gliosarcoma 10 Colorectal Neoplasms 10 Stomach Neoplasms 9 Small Cell Lung Carcinoma 9 Lymphoma 9 Hodgkin Disease 9 Carcinoma, Squamous Cell 9 Urinary Bladder Neoplasms 8

Interventions

durvalumab 2 tremelimumab 1 ceralasertib 1 aflutinib 1 Radiotherapy 1 Pemetrexed 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Non Small Cell Lung Cancer NSCLC × Radiotherapy × 1 year × Clear all

NCT06680050 2025-12-18

AUSTRAL

Mario Negri Institute for Pharmacological Research

Phase 2 Recruiting

Non Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡